Cambridge Healthtech Institute, Bethesda
November 17-19, 2014
Stratified genomic medicine, genome-guided prevention and treatment of complex diseases, is becoming a reality due to the latest achievements in genome research as well as the clinical implementation of powerful technologies such as massively parallel sequencing and digital PCR. The bottleneck of this innovation coming into clinical practice is the current reimbursement uncertainty. The combination of tightening health care budgets and the launch of a large number of expensive molecular tests as well as pricey targeted therapies creates complications for payers to respond in traditional ways. The Third Annual Evidence-Based Reimbursement Summit is designed to bring together major stakeholders from pharmaceutical, biotech, IVD companies, laboratory medicine community and healthcare providers community to exchange opinions and to search for solutions in the innovative medicine commercialization equation.
|
|
|
Invited Speakers:
|
|
Roy Baynes, M.D., Senior Vice President Global Clinical Development at Merck Dane Dickson, M.D., Director, Clinical Science-MolDx, Palmetto GBA Bruce Quinn, M.D., Ph.D., Senior Health Policy Specialist, Foley Hoag, LLP Robert McDonough, Head of Clinical Policy Research & Development at Aetna
|
|